The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the addition of the medication, deferasirox, to
standard antifungal therapy for the infection, mucormycosis, is safe and effective
Phase:
Phase 2
Details
Lead Sponsor:
Los Angeles Biomedical Research Institute Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Collaborators:
Astellas Pharma Inc Gilead Sciences Novartis
Treatments:
Amphotericin B Deferasirox Liposomal amphotericin B